Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...
Wall Street experts highlighted the most important stock market charts to watch into next year. From interest rates to software stocks, here's what Wall Street's top technical experts are watching.
Kleiner and Perkins provided $100,000 on the May closing, and acquired 20,000 shares of preferred stock from Genentech. [6] Swanson was made the president and treasurer of Genentech, and received a $2,500 per month salary, along with 25,000 shares. [6] This marked the end of Swanson's unemployment, and the beginning of his career at Genentech ...
Fluor acquired shares of Genentech Inc. in 1981, [54] and it bought a 10 percent interest in a smelter and refinery facility in Gresik, Indonesia in 1995 for $550 million. In 1994, it invested $650 million with the Beacon Group Energy Investment fund to finance energy projects. [ 35 ]
Genentech (DNA) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy Genentech for $46.8 billion. Genentech's board approved and recommended the deal, which offers $95 per share ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us